Literature DB >> 26394025

NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.

Ravinder Kodela1, Mitali Chattopadhyay1, Carlos A Velázquez-Martínez2, Khosrow Kashfi3.   

Abstract

Aspirin is chemopreventive; however, side effects preclude its long-term use. NOSH-aspirin (NBS-1120), a novel hybrid that releases nitric oxide and hydrogen sulfide, was designed to be a safer alternative. Here we compare the gastrointestinal safety, anti-inflammatory, analgesic, anti-pyretic, anti-platelet, and chemopreventive properties of aspirin and NBS-1120 administered orally to rats at equimolar doses. Gastrointestinal safety: 6h post-administration, the number and size of hemorrhagic lesions in stomachs were counted; tissue samples were frozen for PGE2, SOD, and MDA determination. Anti-inflammatory: 1h after drug administration, the volume of carrageenan-induced rat paw edemas was measured for 5h. Anti-pyretic: fever was induced by LPS (ip) an hour before administration of the test drugs, core body temperature was measured hourly for 5h. Analgesic: time-dependent analgesic effects were evaluated by carrageenan-induced hyperalgesia. Antiplatelet: anti-aggregatory effects were studied on collagen-induced platelet aggregation of human platelet-rich plasma. Chemoprevention: nude mice were gavaged daily for 25 days with vehicle, aspirin or NBS-1120. After one week, each mouse was inoculated subcutaneously in the right flank with HT-29 human colon cancer cells. Both agents reduced PGE2 levels in stomach tissue; however, NBS-1120 did not cause any stomach ulcers, whereas aspirin caused significant bleeding. Lipid peroxidation induced by aspirin was higher than that exerted by NBS-1120. SOD activity was significantly inhibited by aspirin but increased by NBS-1120. Both agents showed similar anti-inflammatory, analgesic, anti-pyretic, and anti-platelet activities. Aspirin increased plasma TNFα more than NBS-1120-treated animals. NBS-1120 was better than aspirin as a chemopreventive agent; it dose-dependently inhibited tumor growth and tumor mass.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspirin; Chemopreventive; GI-sparing; Hydrogen sulfide; Nitric oxide

Mesh:

Substances:

Year:  2015        PMID: 26394025      PMCID: PMC4656078          DOI: 10.1016/j.bcp.2015.09.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  33 in total

1.  Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Authors:  Mitali Chattopadhyay; Carlos A Velazquez; April Pruski; Kamran V Nia; Khaled R Abdellatif; Larry K Keefer; Khosrow Kashfi
Journal:  J Pharmacol Exp Ther       Date:  2010-08-02       Impact factor: 4.030

2.  NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Kenneth R Olson; Khosrow Kashfi
Journal:  Biochem Biophys Res Commun       Date:  2012-02-16       Impact factor: 3.575

3.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

4.  Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

Authors:  G A Kune; S Kune; L F Watson
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

5.  Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.

Authors:  John L Wallace; Giuseppe Caliendo; Vincenzo Santagada; Giuseppe Cirino; Stefano Fiorucci
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

6.  Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Valerio Tazzari; Anna Sparatore; Silvio Trivulzio; Piero Del Soldato; Ferruccio Berti
Journal:  Eur J Pharmacol       Date:  2010-09-15       Impact factor: 4.432

7.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

8.  NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  ACS Med Chem Lett       Date:  2012-01-28       Impact factor: 4.345

9.  Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

10.  Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.

Authors:  Inge Stegeman; Patrick M Bossuyt; Tsung Yu; Cynthia Boyd; Milo A Puhan
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

View more
  21 in total

1.  Pharmacological and toxicological evaluations of the new pyrazole compound (LQFM-021) as potential analgesic and anti-inflammatory agents.

Authors:  Iziara F Florentino; Daiany P B da Silva; José Luís R Martins; Taciane S da Silva; Fernanda C A Santos; Carlos R Tonussi; Géssica A Vasconcelos; Boniek G Vaz; Luciano M Lião; Ricardo Menegatti; Elson A Costa
Journal:  Inflammopharmacology       Date:  2016-09-26       Impact factor: 4.473

Review 2.  Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer.

Authors:  José B Sáenz; Jason C Mills
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 46.802

3.  Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis.

Authors:  Jing-Huan Li; Yan Wang; Xiao-Ying Xie; Xin Yin; Lan Zhang; Rong-Xin Chen; Zheng-Gang Ren
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

4.  Synthesis of 4,5-Dihydro-1H-[1,2]dithiolo[3,4-c]quinoline-1-thione Derivatives and Their Application as Protein Kinase Inhibitors.

Authors:  Svetlana M Medvedeva; Khidmet S Shikhaliev
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

5.  Molecular docking and pharmacological/toxicological assessment of a new compound designed from celecoxib and paracetamol by molecular hybridization.

Authors:  Daiany P B da Silva; Iziara F Florentino; Dayane M da Silva; Roberta C Lino; Carina S Cardoso; Lorrane K S Moreira; Géssica A Vasconcelos; Daniela C Vinhal; Anna C D Cardoso; Bianca Villavicencio; Hugo Verli; Boniek G Vaz; Luciano M Lião; Luiz C da Cunha; Ricardo Menegatti; Elson A Costa
Journal:  Inflammopharmacology       Date:  2018-07-23       Impact factor: 4.473

Review 6.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

7.  NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Gabriela Santiago; Thuy Tien C Le; Niharika Nath; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-02-14       Impact factor: 5.858

Review 8.  The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.

Authors:  Kearsley M Dillon; Ryan J Carrazzone; John B Matson; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

Review 9.  International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.

Authors:  Csaba Szabo; Andreas Papapetropoulos
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 10.  The Role of Hydrogen Sulfide in Respiratory Diseases.

Authors:  Saadullah Khattak; Qian-Qian Zhang; Muhammad Sarfraz; Pir Muhammad; Ebenezeri Erasto Ngowi; Nazeer Hussain Khan; Saqib Rauf; Yi-Zhen Wang; Hui-Wen Qi; Di Wang; Attia Afzal; Xin-Ying Ji; Dong-Dong Wu
Journal:  Biomolecules       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.